PDF factsheet
      Z

myocardial revascularization in acute coronary syndrome for all type of patients, clinical trials results

anistreplase versus placebo
UNASEM, 1992
anistreplase IV 30 UI over 5 minutes
versus
placebo
Patients without a previous myocardial infarction, with a typical history of unstable angina and ECG abnormalities indicative of ischemia double blind
Follow-up duration: hospital stay, 1y
Europe
early intervention versus early strategy
ISAR-COOL, 2003
Prolonged (3 to 5 days) antithrombotic pretreatment (“Cooling-Off” strategy) before intervention
versus
early intervention after pretreatment for less than 6 hours
patients with symptoms of unstable angina plus either ST-segment depression or elevation of cardiac troponin T levelsopen
Follow-up duration: 1 mo
Germany
early invasive management versus delayed invasive strategy
TIMACS, 2009
NCT00552513
early invasive management: angiography within 24 hours followed by PCI or CABG as appropriate
versus
delayed invasive strategy: angiography after 36 hours followed by PCI or CABG as appropriate
patients with unstable angina or non-ST-segment-elevation MI (NSTEMI) open
Follow-up duration: 6 months
30 countries
immediate invasive management versus delayed invasive strategy
ABOARD, 2009
NCT00442949
immediate catheterization and revascularization
versus
catheterization and revascularization on the next working day (between 8 and 60 hours after enrollment)
patient with non ST-elevation acute coronary syndrome open
Follow-up duration: 1 month
France
OPTIMA, 2009
ISRCTN80874637
immediate angioplasty under triple antiplatelet therapy protection
versus
deferred angioplasty
patients with non-ST-segment elevation acute coronary syndromes eligible for percutaneous coronary interventionopen
Follow-up duration: 30 days
The Netherland, England
intracoronary urokinase versus placebo
TAUSA, 1994
intracoronary urokinase 250000 UI or 500000 UI
versus
placebo
ischemic rest pain with or without a recent (< 1 month) infarction double blind
Follow-up duration: hospital stay
USA
routine invasive strategy versus concervative strategy
ICTUS, 2007
ISRCTN82153174
early invasive strategy
versus
selective invasive treatment strategy
patients with non–ST-segment elevation acutec oronary syndrome and elevated cardiac troponin Topen
Follow-up duration: 12 mo (4y)
Netherlands
FRISC 2, 1999
early invasive treatment strategy: angiography within 7 days aiming for revascularisation
versus
non-invasive treatment strategy: angiography only in patients with refractory or recurrent symptoms despite maximum medical treatment or severe ischemia during exercise test before discharge
patients with non–ST-segment elevation acutecoronary syndromeOpen
Follow-up duration: 24 mo
Scandinavia
NQWMI (Eisenberg), 2005
Invasive (angiography at days 2 to 5)
versus
Noninvasive (stress testing at day 2 to 5)
patients with non–Q-wave myocardial infarctionopen
Follow-up duration: 12 months
Canada
RITA 3, 2002
ISRCTN07752711r
routine angiography followed by revascularisationage/pj
versus
conservative strategy (ischaemia-driven or symptom-driven angiography€S
patients with non–ST-segment elevation acutecoronary syndromeopen
Follow-up duration: 24 mo (60 mo)
UK
TACTICS-TIMI 18, 2001
early invasive management strategy
versus
conservative management strategy
patients with non–ST-segment elevation acute coronary syndromeopen
Follow-up duration: 6 mo
9 countries
TRUCS, 2000
invasive strategy
versus
conservative strategy
patients with non–ST-segment elevation acute coronary syndrome in geographically isolated hospitals without cardiac surgical facilities
Follow-up duration: 12 mo
Greece
VINO, 2002
first day angiography / angioplasty strategy
versus
early conservative therapy
patients with non–ST-segment elevation acute coronary syndromeopen
Follow-up duration: 6 mo
Czech Republic
routine invasive strategy - noncomptemporary versus concervative strategy
MATE, 1998
early triage angiography and subsequent therapies based on the angiogram
versus
conventional medical therapy
acute MI ineligible for thrombolytic therapy within 24 h of symptomsopen
Follow-up duration: 21 mo
US
TIMI 3B (PTCA), 1994
Early invasive strategy: systematic angiography (18-48h after randomisation) and revascularisation (PTCA or CABG)
versus
Early elective strategy: angiography and revascularisation only in case of ischemic recurrence (see paper)
patient with unstable angina or non Q wave MI within 24hrs of onsetOpen
Follow-up duration: 12 mo
USA & Canada
VANQWISH, 1998
invasive management
versus
conservative management: medical therapy with subsequent invasive management if indicated by the development of spontaneous or indicible ischemia within 24-72 hours
Patients with Non–Q-wave myocardial infarctionOpen
Follow-up duration: 23 mo
US
surgery versus medical treatment
VA cooperative, 1987
coronary-artery bypass surgery plus medical therapy
versus
medical therapy alone
men with unstable angina pectorisopen
Follow-up duration: 2 years (5,10 years)
US
t-PA versus placebo
Nicklas, 1989
rt-PA, 150 mg/8 h
versus
placebo
patients with rest angina, angiographically documented coronary artery disease and pacing-induced ischemiaDouble blind
USA
Gold, 1987
intravenous recombinant human tissue-type plasminogen activator (rt-PA).
versus
placebo
chest pain at rest with transient ST segment deviation of at least 1 mm
Williams, 1990
tissue-type plasminogen activator (rt-PA) (0.75 mg/kg over 1 hour or (0.75 mg/kg over 1 hour; total dose, 100 mg over 6 hours)
versus
placebo
rest angina and angiographic evidence of coronary stenosis double blind
USA
Freeman, 1992
tissue-type plasminogen activator (t-PA) (0.49 MU/kg for 1 hour followed by 0.07 MU/kg per hour for 9 hours)
versus
placebo
patients with unstable angina double blind
Follow-up duration: in hospital
USA
van der Brand, 1991
alteplase 100 mg in 3 h
versus
placebo
patients with angina at rest, despite bedrest and medical treatment double blind
Follow-up duration: hospital stay
The Netherlands
charbonnier, 1992
rt-PA 100 mg/90 minutes (10 mg bolus + 90 mg/90 minutes
versus
placebo
unstable angina pectoris double blind
Ardissino, 1990
recombinant tissue-type plasminogen activator (rt-PA) followed by heparin
versus
heparin alone
unstable angina refractory to conventional medical treatmentdouble blind
Follow-up duration: in hospital
Italy
TIMI 3B, 1995
tissue-type plasminogen activator (t-PA)
versus
placebo
patients with unstable angina and non-Q wave myocardial infarctionDouble blind
Follow-up duration: 1 year
Topol, 1988
intravenous tissue plasminogen activator (t-PA)
versus
placebo
patients with angina at rest and provocable ischemia (pacing induced) open
Follow-up duration: hospital stay
USA
TIMI 3A, 1993
90-minute front-loaded infusion of t-PA (0.8 mg/kg i.v.; maximum, 80 mg)
versus
placebo
patients with unstable angina or non-Q wave myocardial infarctiondouble blind
Follow-up duration: hospital stay
USA, canada

  Options


in first

in second

  Filter